---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-25-002952"
form_type: "8-K"
ticker: "CMPX"
cik: "0001738021"
company_name: "Compass Therapeutics, Inc."
filed_at: "2025-05-08T23:59:59+00:00"
generated_at: "2026-05-22T04:59:00.820860+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Compass Therapeutics: Tovecimig meets primary endpoint in BTC trial; Q1 net loss $16.6M

## Summary
- Tovecimig + paclitaxel achieved 17.1% ORR (incl. 1 complete response) vs 5.3% for paclitaxel alone (p=0.031) in Phase 2/3 BTC study.
- Secondary endpoints PFS, OS, DoR analyses expected Q4 2025; pre-specified event count not yet met.
- Q1 2025 net loss $16.6M ($0.12/sh), R&D $13.1M (+37% YoY), cash $113M providing runway into 2027.
- CTX-10726 (PD-1 x VEGF-A) pre-IND meeting completed; IND filing expected Q4 2025.
- CTX-8371 Phase 1 dose-escalation advanced to 4th cohort with no DLTs; preliminary data H2 2025.

## SEC filing metadata
- accession: 0001171843-25-002952
- form_type: 8-K
- ticker: CMPX
- cik: 0001738021
- company_name: Compass Therapeutics, Inc.
- filed_at: 2025-05-08T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1738021/000117184325002952/0001171843-25-002952-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1738021/000117184325002952/f8k_050725.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-25-002952
- JSON: https://secwatch.observer/filing/0001171843-25-002952.json
- Plain text: https://secwatch.observer/filing/0001171843-25-002952.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.